Prof. Dr. Irfan Cicin

Prof. Dr. Irfan Cicin
Academic Title :
Prof. Dr.

Prof. Dr. Irfan Cicin is an outstanding specialist in MEDICAL ONCOLOGY at Liv Hospital Topkapı. He has a distinguished career and extensive academic experience in treating various complex cancers and implementing advanced systemic therapies such as immunotherapy, chemotherapy, and hormone therapy.

Education and Academic Qualifications

  • Medical Degree from Cerrahpaşa Faculty of Medicine, Istanbul University (1991–1997)
  • Residency in Internal Medicine from the Faculty of Medicine, Trakya University (1997–2002)
  • Fellowship in Medical Oncology from the Faculty of Medicine, Trakya University (2005–2008)

Areas of Interest

  • Breast cancer treatment
  • Lung cancer treatment
  • Colorectal cancer treatment
  • Gynecological and urogenital cancers
  • Molecular oncology and targeted therapies
  • Cancer immunotherapy
  • Advanced clinical trials and oncology research in Turkey
  • Resident in the Department of Internal Medicine, Trakya University Faculty of Medicine (1997–2002)
  • Specialist Physician in the Department of Internal Medicine, Trakya University Faculty of Medicine (2002–2004)
  • Specialist Physician in Internal Medicine, Etimesgut Military Hospital (2004–2005)
  • Fellow in the Division of Medical Oncology, Trakya University Faculty of Medicine (2005–2008)
  • Medical Oncology Specialist, Elazığ Training and Research Hospital (2008–2010)
  • Associate Professor and Head of the Department of Medical Oncology, Trakya University Faculty of Medicine (2010–2015)
  • Professor (and Head of Department) of Medical Oncology, Trakya University Faculty of Medicine (2015–present)
  • Professor of Medical Oncology and Director of the Clinical Research Center, Istinye University, Liv Hospital Topkapı (2023–present)
  • Turkish Society of Medical Oncology (Former Board Member, Treasurer, and R&D Coordinator between 2014-2018)
  • Turkish Lung Cancer Society
  • Cancer Immunotherapy Society
  • Trakya Breast Diseases Association
  • Author of the book "Side Effect Management in Immunotherapies" (2020), a pioneering medical reference in Turkey.
  • Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised trial.
  • Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study.
  • Is early change in systemic inflammatory markers associated with treatment response in patients who received pazopanib?
Share :